Gender Male
Prior to joining Adjuvance, Dr. Martin served as Chief Medical Officer, President and Director of Dynavax Technologies (NASDAQ: DVAX) where he oversaw clinical development of Heplisav and a TLR9 agonist 1018. He served as President until 2013 when he left to pursue a position as founder and CEO of Great Plains Biotechnology, prior to being
appointed as CEO of Adjuvance Technologies. Prior to Dynavax, Dr. Martin was President of Humabs, and before that he served as Vice President of Development at Chiron where he led the clinical development of inhaled tobramycin powder, a commercially successful cystic fibrosis therapy, among other products. He has also held senior development and research positions at Chiron, Sangamo, Valentis, and SyStemix/GTI. Dr. Martin has overseen the development of three products that achieved either FDA and/or EMA approval, including the adjuvant MF59, which he developed while at Chiron. Dr. Martin received a B.S. in Chemistry and an M.D. from the University of Nebraska. He completed his fellowship in pediatric infectious diseases and molecular microbiology at Washington University in St. Louis.
